ArticleACI open2026
ASTHMAXcelED: A Patient-Facing Asthma Mobile Application with High User Acceptance and Improved Clinical Outcomes.
Article in ACI open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Well-designed mobile health (mHealth) applications can improve patient outcomes; however few clinically tested apps are developed with user-centric design. ASTHMAXcelED is a patient-facing mobile application designed for emergency department (ED) asthma patients. Objectives: We studied user acceptance of the application and compared asthma control and quality of life measures before and after use of ASTHMAXcelED. Methods: This prospective cohort study was conducted in two large urban EDs. Inclusion criteria were patients ≥18 years, English literacy, smartphone access, and discharge from the ED diagnosed with asthma exacerbation. ASTHMAXcelED was downloaded onto participants' phones upon discharge. Asthma symptom control was measured using the Asthma Control Test (ACT). User acceptance of and intention to use the application after the study period was measured using a Unified Theory of Acceptance and Use of Technology. Results: A total of 149 participants were enrolled in the study, of which 124 completed follow-up visits. The proportion of patients with good asthma control (ACT > 19) improved from 27% at baseline to 54% at 4-week follow-up, Conclusion: While using ASTHMAXcelED for 4 weeks, participant's asthma symptom control and quality of life scores improved. Their ED revisit rate and asthma hospitalization during the study period were low. ASTHMAXcelED may be an easily adopted mhealth education platform that can improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.